A Phase 1 Study of CG001419 Administered Orally in Healthy Subjects

A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of CG001419 Administered Orally to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects

This is a dose finding study of CG001419, administered as a single dose, with or without food, and as multiple doses. CG001419 is being tested in healthy volunteers in this trial with the goal of eventually developing the drug for patients with pain if it is found to be safe and well tolerated.

Study Overview

• Status: Completed
• Conditions: Pain Management; Healthy Volunteer Study
• Intervention / Treatment: Drug: Placebo; Drug: CG001419

• Study Type: Interventional
• Enrollment (Actual): 72
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • South Australia
    • Adelaide, South Australia, Australia, 5000
      • CMAX Clinical Research

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Cis-male and cis-female subjects must be 18-65 years, inclusive, at the time of signing the informed consent form (ICF).
• Subjects who are in good general health according to the judgment of the investigator per local guidance, eg, with no clinically relevant abnormalities based on medical history, physical examinations, neurological examinations, clinical laboratory evaluations (hematology and clinical chemistry), vital signs, and 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, would affect subject safety.
• Subjects who have a body mass index (BMI) of 18-32 kg/m2 (inclusive) at screening.

• Male subjects are eligible to participate if they are permanently sterile by vasectomy (at least 6 months), or agree to the following during the study and for at least 90 days after the last dose of study drug:

  1. Refrain from donating sperm

     AND, either:

  2. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR
  3. Agree to use a male condom (contraception/barrier) and should also be advised of the benefit for a female partner to use an acceptable, highly effective method of contraception (of low user dependency or is user dependent), as a condom may break or leak when having sexual intercourse 5. Female subjects are eligible to participate if they are not pregnant or breastfeeding and fall under 1 of the following criteria:

  1. Women of childbearing potential (WOCBP), defined as women physiologically capable of becoming pregnant, must have a negative serum pregnancy test at the Screening visit and a negative urine pregnancy test on Day -1; WOCBP must agree to be abstinent from heterosexual intercourse or use an acceptable, highly effective contraceptive method (of low user dependency or is user dependent) from Screening and not donate eggs until 30 days after the last dose of the study drug.

     OR

  2. Menopausal women must have an elevated serum follicle-stimulating hormone level (FSH >40 IU/mL) level at Screening; if the FSH is not elevated, they are considered to be of childbearing potential (unless permanently sterile).

Exclusion Criteria:

• Clinically significant infection and/or cardiovascular, hematological, renal, hepatic, pulmonary (except recovered childhood asthma), endocrine, reproductive, gastrointestinal, immunological, dermatological, neurological (except migraine), or psychiatric (except depression, which was potentially medicated in the past but didn't require hospitalization) diseases, which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the investigator, unacceptably increase the subject's risk if he/she were to participate in the study.
• History of neuropathy and/or any neurosensory symptoms in the feet or hands.
• Unable to ingest a high-fat meal, such as those who are lactose intolerant (only for subjects in the FE part and if recommended, MAD part too)
• History of disorders that affect gastrointestinal transit time (eg, short bowel syndrome, gastroparesis, irritable bowel syndrome, inflammatory bowel diseases, history of gastric bypass
• Use of prescription drugs, over-the-counter drugs (other than acetaminophen and ibuprofen), herbal medications, or vitamin supplements within 7 days or 5 half-lives, whichever is longer, prior to dosing and antibiotics and systemic steroids within 30 days prior to dosing. Oral contraceptives are permitted. The sponsor, after consulting medical monitor may allow exceptions only if the medication's administration is deemed unlikely to impact the PK results.
• Past or current history or evidence of drug or alcohol abuse, alcohol consumption exceeding 5 units of alcohol on an average per day (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45 mL of alcohol 40%). Use of any non-marijuana illicit drugs (e.g., cocaine, phencyclidine) within 6 months of Screening.
• Donation of over 500 mL of blood within 8 weeks prior to Screening.
• In the opinion of the investigator the subject is unlikely to comply with the study procedures, restrictions, and requirements and is not suitable for entry into the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: CG001419; Part A: Single ascending dose cohorts; food effect cohort; Part B: Multiple ascending dose cohorts	Drug: CG001419; Oral doses
Placebo Comparator: Placebo; Part A: Single ascending dose cohorts; Part B: Multiple ascending dose cohorts	Drug: Placebo; Oral doses

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the safety and tolerability of single and multiple ascending oral doses of CG001419 in healthy subjects	Safety and tolerability based on adverse events (AEs)	Up to 7 days of dosing

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To further characterize the PK of CG001419 in healthy subjects	Cmax	Up to 7 days of dosing
To further characterize the PK of CG001419 in healthy subjects	Tmax	Up to 7 days of dosing
To further characterize the PK of CG001419 in healthy subjects	Area under the concentration curve from 0 to last (AUC0-last)	Up to 7 days of dosing
To further characterize the PK of CG001419 in healthy subjects	Area under the concentration curve from 0 to infinity (AUC0-inf)	Up to 7 days of dosing
To further characterize the PK of CG001419 in healthy subjects	Elimination rate constant (λz)	Up to 7 days of dosing
To further characterize the PK of CG001419 in healthy subjects	Terminal elimination half-life (t1⁄2)	Up to 7 days of dosing
To further characterize the PK of CG001419 in healthy subjects	Apparent oral clearance (CL/F)	Up to 7 days of dosing
To further characterize the PK of CG001419 in healthy subjects	Apparent volume of distribution (Vd/F)	Up to 7 days of dosing

Collaborators and Investigators

• Sponsor: Cullgen Australia Pty Ltd

Study record dates

Study Major Dates

• Study Start (Actual): January 22, 2025
• Primary Completion (Actual): December 5, 2025
• Study Completion (Actual): December 5, 2025

Study Registration Dates

• First Submitted: October 8, 2024
• First Submitted That Met QC Criteria: October 9, 2024
• First Posted (Actual): October 10, 2024

Study Record Updates

• Last Update Posted (Actual): February 20, 2026
• Last Update Submitted That Met QC Criteria: February 18, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Neurobehavioral Manifestations; Perceptual Disorders; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Agnosia
• Other Study ID Numbers: CG001419-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This is a healthy volunteer study being conducted to define the safety profile of the drug. This study is not exploring the activity of our drug in the target indication population (patients with pain). As such, we do not believe there is utility for sharing deidentified IPD from this trial with other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No